CNS (central nervous system) adrenaline (epinephrine) is implicated in a wide range of physiological and pathological conditions. PNMT (phenylethanolamine N-methyltransferase) catalyses the final step in the biosynthesis of adrenaline, the conversion of noradrenaline (norepinephrine) to adrenaline by methylation. To help elucidate the role of CNS adrenaline, and to develop potential drug leads, potent, selective and CNS-active inhibitors are required. The fragment screening approach has advantages over other lead discovery methods including high hit rates, more efficient hits and the ability to sample chemical diversity more easily. In the present study we applied fragmentbased screening approaches to the enzyme PNMT. We used crystallography as the primary screen and identified 12 hits from a small commercial library of 384 drug-like fragments. The hits include nine chemicals with two fused rings and three single-ring chemical systems. Eight of the hits come from three chemical classes: benzimidazoles (a known class of PNMT inhibitor), purines and quinolines. Nine of the hits have measurable binding affinities (∼ 5-700 μM) as determined by isothermal titration calorimetry and all nine have ligand efficiencies of 0.39 kcal/mol per heavy atom or better (1 kcal ≈ 4.184 kJ). We synthesized five elaborated benzimidazole compounds and characterized their binding to PNMT, showing for the first time how this class of inhibitors interact with the noradrenaline-binding site. Finally, we performed a pilot study with PNMT for fragment-based screening by MS showing that this approach could be used as a fast and efficient first-pass screening method prior to characterization of binding mode and affinity of hits.
INTRODUCTION
The identification of suitable starting compounds for development into drugs is a major challenge for drug discovery and development programmes. FBS (fragment-based screening) has been developed as a method for the rapid discovery and subsequent elaboration of hits into quality lead compounds [1, 2] . This approach is based on the principle of screening simple low-molecular-mass compounds that make a few high-quality interactions with the target site. Resulting hits tend to bind to the targets efficiently yet with low affinity and, with a practically designed library, are readily tractable for follow up chemistry [3] . These fragment hits are used as 'anchors' that can be elaborated to fill additional regions of the target site. This results in potent compounds with minimal chemical complexity that can then be developed into drugs. A major challenge in establishing FBS has been the development of sensitive methods to detect the weak binding of hits (with typically milli-to micro-molar binding affinities) [4] . Methods currently used include ITC (isothermal titration calorimetry), NMR, surface plasmon resonance, MS and X-ray crystallography [1, [5] [6] [7] .
FBS-X (FBS by X-ray crystallography) provides the greatest level of information for the elaboration of hit compounds [8] . However, costly infrastructure for crystallization, crystal handling and data collection is required for screening hundreds of crystals in a high-throughput manner. Although many different FBS methods are now used, there have been few reports comparing hits identified against the same specific target by orthogonal methods. NMR is frequently employed as a first-pass screen before detailed structural characterization of hits by X-ray crystallography, and MS has the potential to be applied in a similar manner [9] . Comparative FBS-X and FBS-MS campaigns have not been reported, as far as we are aware, yet there are potentially significant advantages to a combined MS/X-ray screening approach due to their complementary attributes.
Pharmaceutical companies have developed and applied FBS-X with success [10] . An ideal target for FBS-X has an accessible active site, can be crystallized in the apo form and requires only minor conformational changes in the crystal form to accommodate ligand binding. However, many drug targets do not conform to these requirements, including the human enzyme PNMT (phenylethanolamine N-methyltransferase; EC 2.1.1.28; 30.7 kDa), which catalyses the final step in adrenaline (epinephrine) biosynthesis, the methylation of noradrenaline (norepinephrine) to form adrenaline ( Figure 1A ). PNMT has a potential role in a wide range of disease-relevant processes including the central control of blood pressure [11] , pituitary hormone secretion [12] , ethanol intoxication [13] , Parkinson's disease [14] and the neurodegeneration observed in Alzheimer's disease [15] . Structures of recombinant hPNMT (human PNMT) in complex with inhibitors and substrates (e.g. PDB code 1HNN) show that hPNMT has an enclosed active site ( Figure 1B) suggesting that enzyme conformational changes may be needed for ligands to bind [16] . Apo crystals are not readily available because we were unable to crystallize the enzyme in the absence of AdoHcy (S-adenosyl-L-homocysteine), which binds to the cofactor-binding site. Furthermore, when crystals are grown in the absence of an inhibitor or substrate at the noradrenalinebinding site, this site is occupied by a phosphate molecule [17] . However, we were encouraged to attempt FBS-X because we solved the crystal structure of hPNMT (PDB code 3HCD) in complex with the physiological substrate R-noradrenaline by using rapid soaking methods on hPNMT-AdoHcy-PO 4 crystals [17] . We therefore proposed to apply this same soaking method for FBS-X screening of hPNMT, with the aim of identifying novel chemical frameworks for inhibitor design. We also performed an FBS-MS pilot study to determine whether this approach could be used as a more efficient first-pass screen prior to crystallographic analysis of selected hits.
Overall, we showed that FBS-X can be successfully implemented within an academic environment. Our crystallographic screening of the non-ideal enzyme target hPNMT identified 12 hits, including three benzimidazoles (a known class of PNMT inhibitors), and nine of the hits could be characterized by ITC. Five compounds were synthesized to further characterize the benzimidazole class. Our pilot study showed that the orthogonal screening method of FBS-MS could be used as an even more efficient first step in an FBS campaign.
EXPERIMENTAL

Materials
The FBS library was purchased from ActiveSight (a Rigaku company), and comprised 384 compounds with a mean molecular mass of 142 Da and of predominantly rigid low-complexity (see the Supplementary Table Library at http://www.BiochemJ. org/bj/431/bj4310051add.htm); all compounds were provided as 200 mM stock solutions in 100 % DMSO and as cocktails of four fragments each at 50 mM in 100 % DMSO. All the compounds are also available for purchase directly from SigmaAldrich. For chemical syntheses, all reagents and solvents used were reagent grade and of the highest purity commercially available. 4-Methoxybenzene-1,2-diamine was sourced from Alfa Aesar, all other compounds and reagents were sourced from Sigma-Aldrich.
Crystallization of hPNMT
C-terminally His 6 -tagged hPNMT was expressed and purified as described previously [18] . The protein was concentrated to 50 mg/ml and mixed with AdoHcy (to a final concentration of 2 mM) taking the final concentration of protein to 40 mg/ml or 1.25 mM. The protein mixture was crystallized by hanging drop vapour diffusion using QIAGEN EasyXtal Tool crystallization trays for ease of soaking. Drops comprised 1.5 μl of protein and 1.5 μl of precipitant equilibrated over 400 μl of precipitant solution {4-8 % PEG [poly(ethylene glycol)] 6000, 0.25 M LiCl and 0.1 M sodium cacodylate, pH 5.5-6.0}.
FBS by X-ray crystallography
Library screening was conducted blind, in that we made no assumptions about the contents of the library, or what compounds might be expected to bind PNMT. Prior to screening, control experiments were performed using known hPNMT inhibitors to confirm that ligands could be soaked into hPNMT-AdoHcy-PO 4 crystals and that the solvents used for fragment screening and cryoprotection did not interfere with binding. Crystals (∼ 0.25 mm in each dimension) were transferred into 1 μl of soaking solution. Crystal soak solutions were prepared by adding 1 μl of fragment cocktail to 9 μl of stabilizing solution, taking the final concentrations to 6.6 % PEG 6000, 0.3 M LiCl, 0.1 M sodium cacodylate, pH 5.7, 4 × 5 mM fragments and 10 % (v/v) DMSO. Crystals were soaked for 15 min.
Crystals were cryoprotected by transferring directly from the soak solution into mother liquor supplemented with 25 % ethylene glycol for 10-15 s before being flash-cooled. Data for hPNMTAdoHcy-PO 4 were measured from a crystal transferred directly into the cryoprotectant solution without undergoing a soak step. X-ray diffraction data from hPNMT crystals were measured using the UQ ROCX Diffraction Facility or the Australian Synchrotron. At the UQ ROCX Diffraction Facility, crystals were irradiated with X-rays of wavelength 1.542 Å (1 Å = 0.1 nm) generated from a Rigaku FR-E Superbright copper rotating anode generator operating at 45 kV, 45 mA and data were measured using one of two alternate methods: (i) crystals were flash-cooled by plunging into liquid nitrogen and placed on the camera using a Rigaku ACTOR TM crystal mounting robot, X-rays were focused with Osmic Vari-Max HF optics and diffraction data measured on a Rigaku Saturn 944 CCD (charge-coupled-device) detector; or (ii) crystals were flash-cooled on the camera in the gaseous nitrogen stream at 100K, X-rays were focused with Osmic HiRes 2 Confocal Max-Flux TM optics and diffraction data measured with a Rigaku R-AXIS IV ++ imaging plate area detector. Data collected at UQ ROCX Diffraction Facility were processed using Crystal Clear (Rigaku). Data collected at the Australian Synchrotron were measured at 100K with X-rays of wavelength 0.95667 Å on beamline 3BM1 [19] using a MAR 165 CCD detector, and processed using HKL2000 [20] . Crystals diffracting to better than 2.7 Å resolution were used for data collection.
Phasing and automatic structure solution were carried out using MIfit (ActiveSight). The structures were solved by molecular replacement using the structure of hPNMT-AdoHcy-SK&F29661 (PDB code 1HNN), with the inhibitor and waters removed, as the starting model. Active-site density was individually evaluated and assessed for the presence or absence of a ligand. If density indicating a bound fragment was present, ligands were modelled manually using COOT [21] and coordinates and refinement parameters were generated by PRODRG [22] and PHENIX [23] . Further refinement was carried out using PHENIX [23] . Cross-validation was done by R-free analysis from 5 % of the reflections set aside from refinement.
Where density was present at the active site but did not unambiguously identify the bound ligand from the four compounds in the cocktail, a deconvolution step was performed. This involved collecting data from crystals soaked in solutions containing the individual compounds (rather than the cocktail of four compounds). In these cases, the final concentration of the compounds in the soak solution was increased to 20 mM rather than the 5 mM concentration used in the cocktail screen. The higher concentration generally resulted in improved density. Deconvolution also allowed identification of the binding of more than one fragment per cocktail.
Structure determination of hPNMT in complex with elaborated benzimidazoles
Compounds 13-17 were designed and synthesized (see below for details of synthesis) to further characterize the binding of benzimidazoles to hPNMT. The crystal structures of these compounds in complex with hPNMT were determined as follows. Crystals of hPNMT-AdoHcy-PO 4 were soaked in a solution of the synthesized compounds as described above for fragment screening. In this case, compounds were solubilized at 100 mM in 50 % DMSO/water and used to prepare soak solutions of final concentrations 6.6 % PEG 6000, 0.3 M LiCl, 0.1 M sodium cacodylate, pH 5.7, 5-10 mM compounds and 2.5-5 % DMSO.
Crystals were cryoprotected, diffraction data collected and processed, and structures solved and refined at the UQ ROCX diffraction facility using method (ii) described above, with the exception that phasing was carried out using PHENIX [23] and structures were solved by difference Fourier methods. The procedure in this case was to model and refine the structure of the protein first, followed by addition of water molecules, then AdoHcy and finally the ligand. The criteria used to include a water molecule were: the presence of 2F o −F c density at 1σ and F o −F c density at 3σ and at least one possible hydrogen bond within 3.2 Å. Cross-validation was performed as described above. All of the crystal structure electron density maps revealed density indicative of AdoHcy at the cofactor-binding site and density consistent with a benzimidazole bound at the noradrenaline-binding site.
FBS by MS
MS was performed on an APEX ® III 4.7 Tesla FTICR mass spectrometer (Bruker Daltonics) fitted with an Apollo TM ESI (electrospray ionization) source operated in positive ion mode. XMASS NT V6.1.2 MS software on a PC platform was used for data acquisition. Broadband excitation was used to analyse a mass range from m/z 50-6000 and each spectrum was an average of 64 transients (scans) with 512 000 data points acquired in low-resolution mode with an acquisition time of approx. 4 min/sample. Samples were infused into the ESI source at 2 μl/min. Nitrogen was used as both the drying gas (125
• C) and nebulizing gas. Relevant parameters include a 10 4 -fold pressure reduction between source and analyser regions with an ESI source pressure (10 −7 kPa) and high-vacuum analyser region pressure (6 × 10 −11 kPa). Agilent ESI tuning mix (Santa Clara) was used for an external three-point calibration. The hexapole ion accumulation time was 3 s.
To confirm correct ESI-MS parameter adjustment, parameters were optimized using a known hPNMT ligand (7-aminosulfonyl-3-ethyl-1,2,3,4-tetrahydroisoquinoline; K i of 1.8 μM) [24] . Fragments analysed (Supplementary Figure  S1 at http://www.BiochemJ.org/bj/431/bj4310051add.htm) were selected to include a range of FBS-X-positive and -negative hits. A total of 12 fragments were provided with no indication as to which compounds were hits by FBS-X. A stock solution of 31.5 μM hPNMT was prepared in 10 mM ammonium acetate (pH 7); stock solutions of AdoHcy and each of the 12 fragments (representing three of the FBS-X cocktails) were prepared in methanol. Aliquots of all solutions were used immediately or stored at −30
• C. Samples for MS analysis were prepared as follows: 3 μM hPNMT, 0 or 30 μM AdoHcy and 300 μM (100 equiv.) fragment in a total volume of 100 μl. Samples were incubated at room temperature (25
• C) for 30 min prior to MS analysis. A total of 24 MS datasets were acquired to analyse the 12 fragments (i.e. with and without added AdoHcy cofactor). The protein consumption per 100 μl sample was 0.01 mg, however, this sample volume was prepared for convenience and could be reduced as the consumed sample volume was 8 μl per MS acquisition (4 min acquisition at 2 μl/min).
If a hPNMT-fragment or hPNMT-AdoHcy-fragment noncovalent complex is formed in solution then the complex was observed in the ESI mass spectrum. The mass difference between the peaks for the unbound hPNMT and the hPNMTfragment ( m/z) can be multiplied by the charge state to give directly the molecular mass of the binding fragment i.e. M r fragment = m/z × z to provide confirmation of the identity of the hit fragment. Complexes with AdoHcy were similarly treated to identify and confirm the fragment hits. ESI-FT (Fourier transform) MS analysis of a solution containing 3 μM hPNMT yielded the ESI positive ion mass spectrum shown in Supplementary Figure  S2 (A) at http://www.BiochemJ.org/bj/431/bj4310051add.htm. Peaks corresponding to the 13 + to 10 + charge states of hPNMT were observed. The ESI-FTMS spectrum of 3 μM hPNMT with added 30 μM AdoHcy yielded the ESI positive ion mass spectrum shown in Supplementary Figure S2 (B) and, as an example, the ESI-FTMS mass spectrum of a hPNMT-AdoHcy-hit (compound 6) solution is shown in Supplementary Figure S2 (C). In this spectrum each charge state consists of a peak corresponding to hPNMT-AdoHcy and a peak corresponding to the hPNMTAdoHcy-fragment non-covalent complex. Actual mass values of the peaks observed in Supplementary Figure S2 (C) and calculation of the mass of the fragment hit with compound 6 are given in Supplementary Table S1 at http://www.BiochemJ. org/bj/431/bj4310051add.htm.
ITC
Compounds found to bind hPNMT by FBS-X or FBS-MS were subsequently analysed by ITC. ITC was carried out using a highsensitivity MicroCal (GE Healthcare) iTC 200 system at 25
• C. Purified protein at a concentration of 200 μM plus 600 μM AdoMet (S-adenosyl-L-methionine) in 20 mM Tris/HCl, pH 7.2, 1 mM EDTA and 4.3 % DMSO were loaded into the sample cell (V cell , reaction cell volume of ≈ 200 μl). DMSO in the sample was calibrated to match the residual DMSO after fragment dilutions. The fragment hit at 1.5-3 mM in the same buffer was then titrated into the sample cell with 20 × 2.5 μl injections. The heat released was measured and integrated using MicroCal Origin 7.0 software. The association constant (K a ; 1/K d ), enthalpy ( H) and stoichiometry (N) were calculated using a single-site binding model. Measurements were repeated 2-4 times for each ligand and errors calculated as the S.D. from replicate experiments. In each case the protein concentration was fixed as a known quantity and the apparent ligand concentration was adjusted slightly during curve fitting so that the binding stoichiometry was approx. 1 (i.e. an assumption of 1:1 binding was made).
The energies of interaction were calculated from K a values using the Gibbs free energy equation: G = −RT(ln K a ), where R is the gas constant (1.9872 kcal/mol; 1 kcal ≈ 4.184 kJ), T is the temperature of the experiment (298 K) and K a is the association constant for the compound. LE (ligand-binding efficiency) values were calculated according to LE = − G/HA, where G is the free energy of binding (kcal/mol) and HA is the number of heavy atoms (non-hydrogen atoms) in the compound.
Compound synthesis
Benzimidazoles (compounds 13-17, see Figure 5 ) were synthesized using procedures published previously with minor modifications as indicated (see the Supplementary Experimental section at http://www.BiochemJ.org/bj/431/bj4310051add.htm). Generally, an appropriately substituted nitroaniline was reduced by palladium-catalysed hydrogenation to the corresponding phenylenediamine. The phenylenediamine derivative was condensed with cyanogen bromide to form the desired 2-aminobenzimidazole as the hydrobromide salt. Methoxy-substituted 2-aminobenzimidazoles were converted to their corresponding phenol derivatives using 48 % hydrogen bromide. Diamine compound 20 (0.18 g, 1.0 mmol) was dissolved in acetonitrile (20 ml) and water (5 ml) and cooled to 0
• C. Cyanogen bromide in acetonitrile (5M, 0.20 ml, 1.0 mmol) was added dropwise over 5 min. The reaction mixture was warmed to room temperature and stirred overnight. The solvents were evaporated under reduced pressure to give 2-amino-5(6)-chloro-7(4)-methoxybenzimidazole · hydrobromide (compound 21 · HBr) as a brown solid (0.30 g), which was used for the next synthetic step without further purification, m.p., 68-70 
RESULTS
FBS-X
For the FBS-X experiments, we used crystals of hPNMT grown in the absence of inhibitor or ligand for the noradrenalinebinding site. The crystal structure resulting from such crystals reveals a phosphate molecule bound in the noradrenaline-binding site ( Figure 2) ; the phosphate apparently co-purifies with the enzyme during an affinity purification step. The phosphate forms favourable interactions with the side chains of Lys 57 and Asn 39 . For a hit to be detected in the FBS-X experiments, one or more of the four fragments of the cocktail must displace the The hPNMT target binding site for inhibitors is shown for the enzyme crystallized in the absence of inhibitor/substrate. This crystal form was used for FBS-X screening. The phosphate molecule in the noradrenaline site must be displaced by a soaked fragment for a hit to be detected.
Table 1 Statistics for FBS-X screening on hPNMT
The hit rate is calculated on the basis of 12 hits from 376 screened compounds.
Parameter Results
Number Of the 96 cocktails containing four compounds (384 compounds in total) in the library, X-ray diffraction data were collected for 94 cocktails ( Table 1) . Two of the 96 cocktails caused crystal cracking during the soak, preventing high-resolution diffraction data measurement. Owing to the high-throughput nature of the screen, these two cocktails were not considered further. Evaluation of the eight compounds in these two cocktails will be investigated in another study. A total of 16 of the 94 cocktail soaks gave electron density suggestive of hits, i.e. binding of a chemical to the noradrenaline-binding site. The chemical identity of two of the hits was obvious from the initial X-ray data. An additional 51 datasets were measured to deconvolute hits where it was not clear which compound of the cocktail had bound or to measure higher resolution data for confirmed hits. During this process, four of the initially identified hits were found to be false positives. In summary, a total of 12 compounds (out of a possible 376) were identified as binding in the target site of hPNMT, giving a hit rate of 3.2 % for the FBS-X process. The 2F o −F c maps showing the ligand density for these 12 hits are provided as Supplementary Figure S3 at http://www.BiochemJ.org/bj/431/bj4310051add.htm. Summary statistics for the X-ray data are given in Table 1 and data collection and refinement statistics for the 12 hit crystal structures are included as Supplementary Table S2 . The structures of the 12 hits and their binding mode to hPNMT are shown in Figure 3 .
Analysis of fragment hits
The 12 fragment hits all bind the noradrenaline-binding pocket of hPNMT, the same site as other structurally characterized hPNMT inhibitors. Furthermore, all 12 fragments bind within the same region of the pocket ( Figure 4A ). All 12 fragment hits contain either or both a five-or six-membered aromatic ring, sandwiched between the side chains of Phe 182 and Asn 39 . In this position, the rings form π-π stacking interactions with the side chain of Phe 182 . The importance of this interaction is evident in the structure of 6-chloro-oxindole (compound 4) bound to hPNMT (Figure 3) . Unlike other ligand-bound hPNMT structures, there are no direct hydrogen-bond interactions formed between compound 4 and hPNMT. In addition to the π-π stacking interactions between the benzene ring and Phe 182 , the only other interaction that might contribute to binding of compound 4 is a hydrophobic interaction between the chlorine atom and the aromatic ring of Tyr 222 . Three chemical frameworks are present in more than one fragment hit: (i) the benzimidazole core (compounds 6, 7, and 9); (ii) the purine core (compounds 2 and 10); and (iii) the quinoline core (compounds 1, 3 and 11). Despite different substituents, the benzimidazole-based fragments all bind in the same orientation within the active site. In contrast, the binding modes of the two purine-based fragments and the three quinoline fragments vary. This variation allows different functional groups to make favourable interactions (e.g. see compounds 2 and 10, in Figure 3 ) demonstrating that the presence of substituents can alter the binding pose of a core fragment. It should also be noted that the library used for FBS-X screening contains a further ten benzimidazole compounds, none of which were found to bind the noradrenaline site. Similarly, the screening library also contained other quinolines and purines that did not bind to the target site under the conditions used for FBS-X. The observation that different substituents affect binding of compounds to PNMT provides further validation for the specificity of hits identified by FBS-X and may be useful for structure-activity relationship analysis in the development of more potent inhibitors.
Superposition of the fragment hits demonstrates how opposite ends of the noradrenaline pocket bind different chemical functionalities ( Figures 4A and 4B [28] [29] [30] .
In some cases, we found unfavourable contacts between the fragments and hPNMT residues. Many unfavourable interactions resulted from clashes with the hydroxy group of Tyr 35 , which is close to the hydrophobic residues Val 53 , Met 258 , Val 269 and Val 272 . We also observed cases where the electron density for all or part of the fragment was weak. For example, density for the flexible chain of formanilide (compound 8) is weak. In two other cases, 1-aminoisoquinoline (compound 3) and 2-hydroxynicotinic acid (compound 12), the fragments adopt different binding poses in the two hPNMT molecules in the asymmetric unit. This may be due to a lower affinity of these ligands compared with other hits. Finally, for 4-bromo-1H-imidazole (compound 5), it was difficult to determine from the electron density alone the correct position of the ring nitrogen atoms because the compound fits the density equally well in two orientations, rotated 180
• around the long axis. Compound 5 was modelled in one orientation on the basis of predicted favourable interactions (see Figure 3) .
Water molecules in the active site are important because they can indicate potential areas for favourable elaboration of fragments. We found that many water molecules are conserved across the 12 enzyme-fragment structures ( Figure 4C ). There are five major water-binding sites, four of which are located in the hydrophilic region of the binding pocket described above. These four sites, show the greatest level of conservation across the 12 structures, and mediate interactions with Glu 185 , Glu 219 and Asp 267 . The presence of defined water-binding pockets suggests that these regions favour ligand interactions and would probably be amenable to interactions with elaborated inhibitors.
FBS by MS
MS has high sensitivity and a wide dynamic range and can be used to detect non-covalent complexes with a K d in the range from 10 nM to 1 mM [9] . We were interested in using MS as a first-pass FBS method, so we performed a pilot study on hPNMT to ascertain whether MS could identify the same hits as FBS-X. For proof-of-concept, an ESI-FTMS analysis was conducted on a subset of 12 of the 384 fragments from the library. The 12 fragments were intentionally chosen to include several FBS-X hits. ESI-FTMS screening was conducted blind in that the researcher collecting and analysing the data did not know which of the 12 compounds were FBS-X hits. Of the 12 fragments tested, FBS-X identified four fragments as hits (compounds 1, 6, 11 and 12; Figure 3 ), three of which were detected by ESI-FTMS on first inspection of the data (compounds 1, 6 and 12). The fourth FBS-X hit, compound 11, was detected upon re-evaluation of the ESI-FTMS spectra, although it was identified as a weak complex. In addition, ESI-FTMS identified two other hits (Supplementary Figure S3) ; these two fragments were not identified by FBS-X.
ITC evaluation of fragment hits
To confirm and characterize further the 14 fragment hits (12 identified by FBS-X and the two identified by ESI-FTMS), and to prioritize the fragment hits for follow up chemistry and optimization, ITC was used to determine their dissociation constants (K d ) for hPNMT, and thermodynamic parameters of binding. All of the nine fragment hits detected by ITC demonstrated favourable enthalpic contributions ( Figure 3 and Table 2 ). Of the 12 FBS-X hits, the measured binding affinities for nine fragments ranged from approx. 5 to 700 μM. Of these, two fragments (compounds 1 and 11) show low-affinity binding (below 200 μM) that results in sub-optimal Wiseman c-values (<1) for accurate affinity determination by ITC and this is reflected in the relatively large errors [31] . Nonetheless the data do allow prioritization of these compounds for followup. Binding of the remaining three FBS-X hits (compounds 4, 8 and 12) could not be detected by ITC. The two additional hits identified by ESI-FTMS were also not detected by ITC. Furthermore, whereas the binding of 4-quinolinol (compound 1) was detected in ITC experiments, and a K d of 0.7 mM was calculated from the ITC measurements, the signal was weak. The two tightest binding fragments with K d values of approx. 5 μM (2-aminobenzimidazole, compound 6, and 2-amino-1-methybenzimidazole, compound 7), are both based on the benzimidazole core. As discussed above, benzimidazoles have been shown previously to inhibit PNMT [32] . The third fragment hit with a benzimidazole core (5-chlorobenzimidazole, compound 9), had a 20-fold lower binding affinity (K d of 97 μM), suggesting that direct and water-mediated hydrogen bonds to the 2-amino groups of compounds 6 and 7 contribute considerably to ligand affinity for hPNMT. The dissociation constants were used to calculate their LE values ( Figure 3 and Table 2 ). The LE values ranged from 0.39 kcal/mol per HA for 4-quinolinol to 0.86 kcal/mol per HA for 4-bromo-1H-imidazole (compound 5). The two tightest binding benzimidazole-based fragments, compounds 6 and 7, had high LEs of ∼ 0.7 kcal/mol per HA.
Elaborated benzimidazole compounds
Three of the identified hits (compounds 6, 7 and 9) contain a benzimidazole ring system. The electron density for these three hits was excellent, and ITC measurements confirmed that all three bind to hPNMT, two of them with very high LE values. Benzimidazoles have been investigated previously as inhibitors of PNMT, although the earlier work was performed on the bovine enzyme [32] . To further characterize the interaction of benzimidazole-based fragments with the human enzyme, a series of compounds (compounds 13-17; Figure 5 ) closely related to the FBS-X benzimidazole hits were synthesized. The 2-amino group was retained in this series because in compounds 6 and 7 it forms direct and water-mediated hydrogen bonds to the enzyme. The binding of compounds 13-17 to hPNMT was evaluated by ITC and X-ray crystallography. The results of these analyses are shown in Figure 5 and data collection and refinement statistics for the structures are included as Supplementary  Table S2 . ITC curves are shown in Supplementary Figure S4 at http://www.BiochemJ.org/bj/431/bj4310051add.htm, and the ITC-derived thermodynamic parameters of the 12 fragment hits and five elaborated compounds are given in Table 2 .
Hydroxy-substituted 2-aminobenzimidazole compounds (compounds 13 and 14)
Superposition of the benzimidazole-based fragments with the fragment hit 4-quinolinol (compound 1), suggested that a hydroxy group added to the 7-or 6-position of compound 6 would interact with Lys 57 and potentially with Tyr 40 . To test this, compounds 13 and 14 were synthesized and their binding characterized ( Figure 5 and Table 2 ). The crystal structures of hPNMT-AdoHcy-compound 13 and hPNMT-AdoHcycompound 14 showed that both these elaborated compounds bound in a flipped binding mode compared with the predicted binding mode, i.e. instead of forming an interaction with Lys 57 , the hydroxy group is oriented away from Lys 57 . In hPNMTAdoHcy-compound 13 the hydroxy group makes no favourable interactions, and sits in a hydrophobic pocket comprising the side chains of Met 258 and Val 269 . This same position is occupied by the chloro substituent of compound 9 when it forms a complex with hPNMT ( Figure 3 ). In addition, the benzimidazole core of compound 13 is shifted away from the hydrophobic pocket compared with the original hit fragment, compound 6. This movement results in an unfavourable interaction between the six-membered aromatic ring and Lys 57 . These changes result in a reduced enthalpic binding contribution of compound 13 compared with compound 6; this is balanced by a smaller entropy loss upon binding with overall a small net decrease in the free energy of binding. This is reflected in a decreased binding affinity and LE of the elaborated compound compared with the original hit (compound 13, K d of 15 μM and LE of 0.60 kcal/mol per HA; compound 6, K d of 6.3 μM and LE of 0.71 kcal/mol per HA), indicating that the hydroxy modification to compound 6 is not favourable for binding.
Similarly, the hydroxy group of compound 14 is not favourable for binding to hPNMT. In the crystal structure of the hPNMT complex, the hydroxy group is unfavourably close to Met 258 and waters are displaced from the hydrogen-bonding network. These changes result in a reduced enthalpic contribution, a reduced binding affinity and a reduced LE compared with the original hit, compound 6 (compound 14, K d of 20 μM and LE of 0.58 kcal/mol/HA). 2 μM) , was similar to the parent compound 6, although the enthalpic and entropic contributions were slightly altered, with a less favourable enthalpy but more favourable entropy.
Hydroxy-and chloro-di-substituted 2-aminobenzimidazole (compound 17)
Di-substitution of the 2-aminobenzimidazole core with the 5-chloro and 7-hydroxy substituents in compound 17, did not significantly improve affinity (K d of 14 μM) compared with the hydroxy substitution alone (compound 13, K d of 15 μM). As a result, the LE was reduced compared with the original, unsubstituted fragment compound 6, and the separately substituted compounds 13 and 15. Despite extensive trials we were unable to measure X-ray diffraction data for hPNMTAdoHcy-compound 17. Crystals soaked in this compound cracked during cryoprotection or gave very weak diffraction, indicating that binding of the compound induces crystal disorder or conformational changes to accommodate compound 17. As no improvement in binding affinity or enthalpic contribution was observed, we did not investigate compound 17 further.
DISCUSSION
Using FBS-X we found that 12 compounds from a library of 374 compounds bound to the noradrenaline-binding site of hPNMT by displacing phosphate from the crystal structure. Our hit rate of 3.2 % is similar to that of other FBS-X campaigns [33] [34] [35] [36] [37] [38] , despite the fact that our target crystal structure was not in the apo form. We also investigated the use of high-sensitivity ESI-FTMS, which has been used previously to screen natural product and combinatorial chemistry libraries against other enzymes [39, 40] . For our proof-of-concept study, we used a subset of the fragment library. ESI-FTMS identified the same four hits found by FBS-X for this subset. FBS-MS data acquisition took only 4 min, so an These results suggest that ESI-FTMS could be used as a filter to generate a short-list for subsequent characterization by X-ray crystallography. This could in theory reduce the number of crystal structures to be measured from ∼ 150 to ∼ 20, thereby saving time, human resources and protein, and making the technique accessible to many more academic laboratories.
Using ITC we determined the dissociation constants of nine of the 12 FBS-X fragment hits. The results showed that the fragments bind with affinities in the high to low micromolar range and all nine hits for which affinity data were measured had LE values 0.4 kcal/mol per HA. Generally, LE values above 0.4 kcal/mol per HA are desirable through the process of optimization [38, 41] . Many of our hits had considerably higher LE values, emphasizing their high quality.
Several of the FBS-X hits are benzimidazoles, a known class of PNMT inhibitor. In 1970, researchers at the MSD (Merck Sharp and Dohme Research Laboratories) showed that benzimidazoles (including 2-aminobenzimidazole, compound 6, and 5-chlorobenzimidazole, compound 9) inhibit bovine PNMT. Thus at 28 μg/ml compound 6 inhibits binding of 0.57 mM DLnormetanephrine to bovine PNMT by 30 % and compound 9 inhibits binding by 57 % [32] . Our FBS-X results identified that these compounds also interact with human PNMT and show for the first time how they bind in the noradrenaline pocket. The MSD study also showed that unsubstituted benzimidazole is an inhibitor of bovine PNMT (28 % inhibition under the conditions described above) [32] . Benzimidazole is one of the 376 compounds in the library used in the present study, but was not identified as a hit by FBS-X. This finding could be explained by one or more of the following: (i) benzimidazole does not inhibit PNMT by binding the noradrenaline-binding site; (ii) the noradrenaline-binding site of the human and bovine enzymes differ sufficiently that they recognize benzimidazole differently; or (iii) the screening method we employed is less sensitive than the assay used to detect inhibition in the bovine enzyme.
Several PNMT inhibitors have been shown to be competitive for noradrenaline binding [42] [43] [44] , although it has been shown that a dichloro-substituted benzimidazole PNMT inhibitor was noncompetitive with noradrenaline and uncompetitive with AdoMet [45] . These early results indicate the possibility of an additional binding site for benzimidazoles. Our data clearly show that the three benzimidazole hits and the elaborated compounds bind at the noradrenaline site. However, the hPNMT crystals used for our studies have AdoHcy (as a cofactor product) bound at the AdoMet site. Furthermore, ITC analysis was performed in the presence of excess AdoHcy. Consequently, if the benzimidazole compounds bind to the hPNMT AdoMet site this would not be identified under the conditions of our experiments.
The improved binding affinity of the designed benzimidazole compound 15 compared with the original compound 6, is largely due to an increased entropic contribution to binding (Table 2 ). Enthalpic optimization is more desirable than entropic opimization in progressing from hit to lead [46] . Typically, enthalpically optimized leads more closely mimic the thermodynamic characteristics of natural protein-ligand interactions, are more soluble and often represent best-in-class compounds in drug discovery programmes [46, 47] . Our results therefore indicate that although compound 15 shows higher affinity than compound 6 this improvement may not necessarily correlate with an improved drug lead.
In summary, we have shown that FBS-X can be implemented successfully within an academic environment on a non-ideal protein target. Using FBS-X we identified 12 hits that bind hPNMT at the noradrenaline site. Our pilot study suggests the screening process could be streamlined further by performing FBS-MS first. Three of the FBS-X hits are from a chemical class of known PNMT inhibitors that provide an unanticipated internal control for the screen. Overall, we structurally and thermodynamically characterized the binding of 17 small molecules to hPNMT, including the first such characterization of the benzimidazole class of compounds bound to the noradrenalinebinding site.
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The data for fragment hit compounds 1-5 were collected in house using the UQ ROCX Diffraction Facility, whereas the data for fragment hit compounds 6-12 were collected at the Australian Synchrotron (3BM1). The completeness is number of measured unique reflections divided by the number of theoretical reflections, expressed as a percentage. R merge = |I obs −I av |/ I av , over all symmetry-related observations. R cryst = |F obs −F calc |/ |F obs |, over all reflections. R free is calculated as for R cryst from 5-10 % of the data excluded from refinement. Values in parentheses are for the highest resolution shell of data. 
